Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.406,32
-0,28%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ GlycoMimetics Inc (GLYC) GlycoMimetics Inc (GLYC) Notizie

GlycoMimetics Inc

GLYC
0,242
0,0255 (11,78%)
24 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
27/11/202420:22EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
12/11/202414:00PRNUSCrescent Biopharma to Present at Jefferies London Healthcare..
07/11/202422:47EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/11/202422:42EDGAR2Form 8-K - Current report
06/11/202423:41EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
06/11/202413:00BWGlycoMimetics Announces New Uproleselan Clinical Data Will..
04/11/202422:26EDGAR2Form SC 13D - General Statement of Acquisition of Beneficial..
04/11/202420:01EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
29/10/202415:00APSBiotech Up Over +100% Premarket Following Merger And Funding..
29/10/202413:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/10/202413:09EDGAR2Form 8-K - Current report
29/10/202412:00BWGlycoMimetics Enters Into Acquisition Agreement With..
29/10/202411:30BWGlycoMimetics Announces National Cancer Institute Phase 2/3..
15/8/202423:01EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
08/8/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/7/202421:55EDGAR2Form 8-K - Current report
30/7/202401:24EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
25/7/202415:00BWGlycoMimetics Announces Strategic Review and Corporate..
13/6/202422:30EDGAR2Form 8-K - Current report
04/6/202415:30EDGAR2Form 8-K - Current report
04/6/202413:00BWGlycoMimetics Announces Comprehensive Results from Pivotal..
29/5/202422:01BWGlycoMimetics to Host Key Opinion Leader Event to Review..
09/5/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202422:01EDGAR2Form 8-K - Current report
06/5/202412:00BWGlycoMimetics Announces Results of Pivotal Phase 3 Study of..
25/4/202413:00BWGlycoMimetics to Report First Quarter 2024 Financial Results..
27/3/202412:00BWGlycoMimetics Reports Highlights and Financial Results for..
13/3/202412:00BWGlycoMimetics to Report Fourth Quarter and 2023 Full Year..
01/3/202415:16EDGAR2Form 8-K - Current report
26/2/202413:00BWGlycoMimetics to Participate in Upcoming Cowen 44th Annual..
12/2/202413:00BWGlycoMimetics Reports Inducement Grant Under NASDAQ Listing..
17/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202413:00BWGlycoMimetics Announces Positive Initial Safety and..
03/1/202413:00GLOBEApollomics Completes Enrollment in Phase 3 Bridging Study of..
02/1/202422:30EDGAR2Form 8-K - Current report
02/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 0,205 Min: 0,205 Max: 0,25
Chiusura: 0,2165

La tua Cronologia

NASDAQ
GLYC
GlycoMimetics
LSE
ON20
Morg.st.b.v 25
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network